Eton Pharmaceuticals, Inc.

Eton Pharmaceuticals, Inc. is a pharmaceutical company dedicated to developing and commercializing treatments for rare diseases. Headquartered in Deer Park, Illinois, USA, the company's mission is to advance healthcare by introducing innovative medicines that are both affordable and accessible to patients, particularly those with underserved rare conditions.

Eton Pharmaceuticals focuses on a diverse portfolio of commercial rare disease products, including Increlex for severe primary IGF-1 deficiency, Alkindi Sprinkle for adrenal insufficiency, Khindivi for adrenocortical insufficiency, Galzin for Wilson disease, PKU Golike for phenylketonuria, Carglumic Acid for N-acetylglutamate synthase deficiency, Betaine Anhydrous for homocystinuria, and Nitisinone for tyrosinemia type 1. The company also maintains a robust pipeline of late-stage development candidates, such as ET-600 for diabetes insipidus, Amglidia for neonatal diabetes mellitus, ET-700 for Wilson disease, ET-800 for adrenal insufficiency, and the ZENEO hydrocortisone autoinjector for adrenal crisis.

Recent notable developments include strong financial performance in late 2025 and early 2026, with significant growth in product sales. The company expanded its rare disease portfolio by relaunching HEMANGEOL and securing U.S. commercialization rights for IMPAVIDO. Sean E. Brynjelsen serves as President, Chief Executive Officer, and Director, with Judith M. Matthews assuming the role of Chief Financial Officer effective June 1, 2026. Eton Pharmaceuticals is strategically positioned as a commercial entity with a dynamic portfolio and pipeline, aiming to become a leading provider of rare disease treatments in the United States.